Advertisement
New Zealand markets close in 1 hour 19 minutes
  • NZX 50

    11,836.75
    -109.68 (-0.92%)
     
  • NZD/USD

    0.5957
    +0.0007 (+0.12%)
     
  • NZD/EUR

    0.5554
    +0.0013 (+0.24%)
     
  • ALL ORDS

    7,849.10
    -88.40 (-1.11%)
     
  • ASX 200

    7,587.30
    -95.70 (-1.25%)
     
  • OIL

    83.80
    +0.23 (+0.28%)
     
  • GOLD

    2,344.40
    +1.90 (+0.08%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • Hang Seng

    17,623.54
    +339.00 (+1.96%)
     
  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     
  • NZD/JPY

    92.9470
    +0.4510 (+0.49%)
     

How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?

In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.